Robertson N - Search Results

1

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ, Carmichael J. Patterson AV, et al. Among authors: robertson n. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):369-72. doi: 10.1016/0360-3016(94)90291-7. Int J Radiat Oncol Biol Phys. 1994. PMID: 8195035

2

The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?

Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. Robertson N, et al. Biochem Pharmacol. 1992 Aug 4;44(3):409-12. doi: 10.1016/0006-2952(92)90429-m. Biochem Pharmacol. 1992. PMID: 1510692

3

Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.

Naylor MA, Adams GE, Haigh A, Cole S, Jenner T, Robertson N, Siemann D, Stephens MA, Stratford IJ. Naylor MA, et al. Among authors: robertson n. Anticancer Drugs. 1995 Apr;6(2):259-69. doi: 10.1097/00001813-199504000-00010. Anticancer Drugs. 1995. PMID: 7795274

4

Manipulation and exploitation of the tumour environment for therapeutic benefit.

Stratford IJ, Adams GE, Bremner JC, Cole S, Edwards HS, Robertson N, Wood PJ. Stratford IJ, et al. Among authors: robertson n. Int J Radiat Biol. 1994 Jan;65(1):85-94. doi: 10.1080/09553009414550121. Int J Radiat Biol. 1994. PMID: 7905915 Review.

5

Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.

Robertson N, Haigh A, Adams GE, Stratford IJ. Robertson N, et al. Eur J Cancer. 1994;30A(7):1013-9. doi: 10.1016/0959-8049(94)90134-1. Eur J Cancer. 1994. PMID: 7946565

6

5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.

Jaffar M, Naylor MA, Robertson N, Lockyer SD, Phillips RM, Everett SA, Adams GE, Stratford IJ. Jaffar M, et al. Among authors: robertson n. Anticancer Drug Des. 1998 Mar;13(2):105-23. Anticancer Drug Des. 1998. PMID: 9524554

7

Targeting hypoxia with a new generation of indolequinones.

Jaffar M, Naylor MA, Robertson N, Stratford IJ. Jaffar M, et al. Among authors: robertson n. Anticancer Drug Des. 1998 Sep;13(6):593-609. Anticancer Drug Des. 1998. PMID: 9755720 Review.

8

Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.

Blancher C, Moore JW, Robertson N, Harris AL. Blancher C, et al. Among authors: robertson n. Cancer Res. 2001 Oct 1;61(19):7349-55. Cancer Res. 2001. PMID: 11585776

9

Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.

Naylor MA, Swann E, Everett SA, Jaffar M, Nolan J, Robertson N, Lockyer SD, Patel KB, Dennis MF, Stratford MR, Wardman P, Adams GE, Moody CJ, Stratford IJ. Naylor MA, et al. Among authors: robertson n. J Med Chem. 1998 Jul 16;41(15):2720-31. doi: 10.1021/jm970744w. J Med Chem. 1998. PMID: 9667963

10

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14. Lancet. 2021. PMID: 34000257 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,368 results

Search Page

Filters